Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study
British Journal of Haematology · 2025-12 · 207 (6) · 2486-2495
DOI: 10.1111/bjh.70154 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 22.09.2025. Verfasst von Celalettin Ustun und 33 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology/Cell Therapy, Department of Medicine, Rush University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Coleman Foundation.
Abstract (Originalsprache)
We investigated the outcomes of patients with advanced systemic mastocytosis (AdvSM) undergoing allogeneic haematopoietic cell therapy (alloHCT) in the US. Twenty‐seven adult (median age, 58 years) patients with AdvSM received alloHCT from 2014 to 2021. Most patients were white (93%), male (63%) and had systemic mastocytosis (SM) with associated haematological neoplasm (SM‐AHN, 70%), received peripheral blood grafts (89%) and non‐myeloablative regimens. KIT mutation was detected in 14 of the reported 16 patients (87.5%). Post‐transplantation cyclophosphamide (PTCy) was used in approximately 50% of the cohort. Approximately 1 year after alloHCT, median bone marrow mast cell burden decreased from 15% pre‐alloHCT to 1.5% (range 0–8) at 1 year post‐alloHCT. The median serum tryptase decreased from 55 ng/mL (range 3–400 ng/mL) pre‐alloHCT to 18 ng/mL (range 0–481 ng/mL) at 1 year post‐alloHCT. At 1 year, progression‐free survival (PFS) and overall survival (OS) were 59% (95% confidence interval [CI], 41%–77%) and 74% (95% CI, 56%–89%) respectively. In the subset of patients with SM‐AHN, 1‐year PFS and OS were 74% (52%–91%) and 79% (95% CI, 58%–94%) respectively. The cumulative incidence of relapse/progression for the entire population of patients with SM ( n = 27) was 4% (95% CI, 0–14) at 100 days and 15% (95% CI, 4–31) at 1 year. For the subset of patients with AHN, the cumulative incidence was 11% (95% CI, 1–28) at 100 days and 21% (95% CI, 6–42) at 1 year. Relapse/progression was the cause of death in six of 12 patients (5 died of AHN and 1 died of SM progression). Eighteen and nine patients received a KIT inhibitor before alloHCT and after alloHCT respectively. In addition, six patients received a KIT inhibitor for the treatment of relapse/progression of SM after alloHCT. Although it is difficult to delineate the exact effect of alloHCT and KIT inhibitors because of the size of the study in this era, the use of alloHCT and KIT inhibitors pre‐ and post‐ alloHCT is increasing. In the near future, larger studies are required to provide further insights into this subject.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology/Cell Therapy, Department of Medicine, Rush University, Chicago, Illinois, USA.
- CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.
- Division of Hematology/Oncology, Department of Medicine, MUSC, Charleston, South Carolina, USA.
ORCID-Profile: Celalettin Ustun, Hassan Alkhateeb, Gautam Borthakur, Kalyan V Nadiminti, Taiga Nishihori, Andrew Trunk, Mehdi Hamadani, Betul Oran
Förderung
- NCI NIH HHS
- Coleman Foundation
Zitieren
APA
Ustun, C., Zhang, M. J., Peterson, A., Baek, A., Agha, M., Alkhateeb, H., Chhabra, S., Coltoff, A., de Lima, M., Gandhi, A., Ho, V., Kassim, A., Lin, A., Gowda, L., Borthakur, G., DeAngelo, D. J., McGuirk, J., Mensah, F., Nadiminti, K. V., …, & Burns, L. J. (2025). Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study. British Journal of Haematology, 207(6), 2486-2495. https://doi.org/10.1111/bjh.70154
Vancouver
Ustun C, Zhang MJ, Peterson A, Baek A, Agha M, Alkhateeb H, et al. Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study. British Journal of Haematology. 2025;207(6):2486-2495. doi:10.1111/bjh.70154
BibTeX
@article{Ustun2025,
author = {Ustun, Celalettin and Zhang, Mei-Jie and Peterson, Andrew and Baek, Alexander and Agha, Mounzer and Alkhateeb, Hassan and Chhabra, Saurabh and Coltoff, Alex and de Lima, Marcos and Gandhi, Arpita and Ho, Vincent and Kassim, Adetola and Lin, Adam and Gowda, Lohith and Borthakur, Gautam and DeAngelo, Daniel J and McGuirk, Joseph and Mensah, Felix and Nadiminti, Kalyan V and Nishihori, Taiga and Pantin, Jeremy and Trunk, Andrew and Uberti, Joseph and Marcucci, Guido and Gotlib, Jason and Akin, Cem and Hamadani, Mehdi and Pullarkat, Vinod and Valent, Peter and Grunwald, Michael and Juckett, Mark and Oran, Betul and Saber, Wael and Burns, Linda J},
title = {Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study},
journal = {British Journal of Haematology},
year = {2025},
volume = {207},
number = {6},
pages = {2486--2495},
doi = {10.1111/bjh.70154}
}
EUVIMED